

PRESS RELEASE

EBIDTA Doubles, Sales Grow for Indoco in Q1FY21

Mumbai, 11th August 2020: During the first quarter of FY 2020-21, Indoco Remedies revenues grew by 7.9 % at ₹ 267 crores, as against ₹ 247 crores, same quarter last year. EBIDTA to net sales for the quarter is 18.3 % at ₹ 48.9 crores, compared to 9.2 % at ₹ 22.7 crores, same quarter last year. The Company recorded a net profit of ₹ 17.23 crores, as against ₹ 2.2 crores, same quarter last year.

Commenting on the 1st quarter FY21 results, Aditi Panandikar, Managing Director, Indoco Remedies Ltd., said, “In the first quarter, the Company could register a growth of 7.9 % in revenues inspite of Covid-19 crisis. In these challenging times, our teams used digital platforms effectively to establish communication with the customers and maintained uninterrupted supplies of medicines in India and across the world.”

For the quarter ended Jun’20, the financials are as under:

(₹ in Crores)

Particulars	Apr’20 - Jun’20	Apr’19 - Jun’19	Gw %
Net Revenues	266.8	247.2	7.9
EBIDTA	48.9	22.7	114.8
Operating Profit	34.2	10.8	218.2
Profit After Tax	17.2	2.2	690.4
EPS (Face value ₹ 2/-) (Not annualized)	1.87	0.24	

About Indoco Remedies Limited:

Indoco Remedies Ltd., headquartered in Mumbai, is a fully integrated, research-oriented pharma Company with presence in 55 countries. Indoco, a USD 145 million Company, employs over 5500 people including more than 300 skilled scientists.

The Company has 9 manufacturing facilities, 6 of which are for FDFs and 3 for APIs, supported by a state-of-the-art R&D Centre and a CRO facility. The facilities have been approved by most of the Regulatory Authorities including USFDA and UK-MHRA. Indoco develops and manufactures a wide range of pharmaceutical products for the Indian and international markets. It generates more than 70 million prescriptions annually from over 3,00,000 doctors belonging to various specialties. Indoco has 9 domestic marketing divisions with a strong brand portfolio in various therapeutic segments including Respiratory, Anti-Infective, Dental Care, Pain Management, Gastro-intestinal, Ophthalmic, Cardiovascular, Anti-Diabetics, Anti-Obesity, etc. Top Indoco brands include Cyclopam, Febrex Plus, Sensodent-K, Oxipod, Cital, ATM, Cloben-G, Sensoform, Sensodent-KF, Karvol Plus, Glychek, Kidodent, Carmicide, Bactogard, etc. On the international front, Indoco has tie-ups with large generic companies across the globe.

For more details on Indoco, you may visit www.indoco.com

For Media Inquiries Please Contact:

Vilas V. Nagare

Mobile: 9820215745

E-mail: vilasn@indoco.com / corpcom@indoco.com